A new study led by scientists from the Florida campus of The Scripps Research Institute (TSRI) sheds light on a signaling circuit in cells that drives therapy resistance in prostate cancer. The researchers found that targeting the components of this circuit suppresses advanced prostate cancer development.
In a clinical trial, men with newly diagnosed, metastatic, hormone-sensitive prostate cancer who received chemotherapy straight away alongside hormone-blocking therapy lived more than a year longer than men who followed the standard treatment – which is to wait until the tumors have become resistant to hormone therapy before receiving chemotherapy.Continue reading
Men who show signs of chronic inflammation in non-cancerous prostate tissue may have nearly twice the risk of actually having prostate cancer than those with no inflammation, according to results of a new study.Continue reading